Author: Rachelle Ramirez

Poster-Non-imaging Biomarkers

Non-Right-Handedness May be Associated with More Severe Multiple Sclerosis

Background: Because handedness non-right-handedness (NRH) is associated with increased incidence of other auto-immune disorders, Shirani et...

Read More

Poster-Quality of Life and Outcomes

Characterizing Activities of Daily Living in MS Patients with Processing Speed Scores Above and below a Threshold Previously Shown to Predict Employment Status

Background: Cognitive impairment can occur early in the course of multiple sclerosis (MS) and worsen progressively over time, impacting...

Read More

Poster-Symptom Management

Nabiximols, a Cannabis-Based Complex Botanical Mixture and MS Spasticity: How Does It Work?

Background: Nabiximols is a complex botanical mixture containing delta-9-tetrahydrocannibinol (THC), cannabidiol (CBD), other plant-derived...

Read More

Poster-Symptom Management

Identifying and Characterizing Fatigue in Patients Diagnosed with Multiple Sclerosis on Disease-Modifying Therapies Using Real World Evidence

Background: Fatigue is a common symptom in patients with Multiple Sclerosis (MS). Payor databases represent an important source of real...

Read More

Poster-Symptom Management

Implementation of a Depression Screening Tool (PHQ-9) for Adult Multiple Sclerosis Patients at an Outpatient Neurology Clinic.

Background: Depression is the most common symptom in Multiple Sclerosis (MS) patients with reported lifetime prevalence of 25-50%....

Read More

Poster-Symptom Management

Is a Light Hand on the Wheels Enough? Postural Sway in Standing with Different Methods of Walker Use in Multiple Sclerosis and Controls

Background: Individuals with Multiple Sclerosis (iMS) have increased postural sway and are at higher risk for falls. Some iMS describe...

Read More

Poster-Symptom Management

Arbaclofen Extended-Release for Spasticity in Multiple Sclerosis: Responder Analysis of a Phase 3 Randomized, Placebo-Controlled Clinical Study OS440-3004

Background: Arbaclofen is the active R-enantiomer of racemic baclofen. Arbaclofen extended-release (ER) tablets have demonstrated efficacy...

Read More

Poster-Self-care

Summary of Diet Intervention Studies in Multiple Sclerosis from the National MS Society Nutrition Wellness Subgroup

Background: Increasing evidence suggests that lifestyle factors such as dietary patterns and exercise impact the risk and course of...

Read More

Poster-Symptom Management

Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: A Randomized, Multi-Center, Placebo-Controlled Clinical Trial (Study OS440-3004)

Background: Arbaclofen, the active R-enantiomer of baclofen, a racemic g-aminobutyric acid-B (GABAB) receptor agonist, has been a mainstay...

Read More

Poster-Symptom Management

Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: An Open-Label Safety Study (Study OS440-3005)

Background: Despite pharmacologic therapy, people with multiple sclerosis (MS) often experience spasticity, which can worsen with longer...

Read More